Introduction

HIV include lamivudine (3TC), emtricitabine (FTC) or tenofovir disoproxil fumarate (TDF).
FTC is structurally similar to 3TC, but has a longer half-life [3] , and selects the YMDD mutation less often and less rapidly [4] . Although FTC is currently not approved for the treatment of HBV, it induces a rapid and sharp reduction in HBV DNA, and more than onehalf of HBV-monoinfected patients treated with FTC maintained suppression of HBV DNA at 48 weeks [4] . There is limited randomized data on the efficacy of FTC or TDF plus FTC in ARV-naive, HIV-HBV-coinfected patients. In this trial, we examined the efficacy and safety of FTC alone or in combination with TDF in treatment-naive HIV-HBV-coinfected patients starting ART and found that patients who received TDF/FTC combination therapy were significantly more likely to have an undetectable HBV DNA at week 48.
Methods
Patients
Patients were recruited from the HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre (Bangkok, Thailand) and the Chulalongkorn King Memorial Hospital, Chulalongkorn University (Bangkok, Thailand). HIV-infected men and women with chronic hepatitis B (hepatitis B surface antigen [HBsAg] detected on two occasions 6 months apart) and aged between 18 and 70 years were enrolled if they were ARV-naive, had HBV DNA>100,000 copies/ml, creatinine ≤2.0 mg/dl and platelet count ≥50,000 cells/mm 3 . Exclusion criteria were positivity for HCV RNA, immunoglobulin M antibody to hepatitis A virus and other causes of chronic liver disease (autoimmune, α1-antitrypsin deficiency and haemochromatosis), serum alanine aminotransferase (ALT) levels >1,000 U/l, decompensated cirrhosis or α-fetoprotein >3× the upper limit normal (ULN).
Study design
This was a prospective two-arm non-blinded randomized clinical trial to compare the efficacy of FTC or FTC plus TDF over 48 weeks in ARV-naive HIV-HBV-coinfected individuals. The study was originally conducted at three sites in the Netherlands and one site in Thailand. Because of a limited number of eligible participants in the Netherlands, the Netherlands sites were terminated prematurely and only patients enrolled in Thailand were included in this analysis. Patients were enrolled between April 2005 and December 2006. The patients were randomized on a 1:1 basis to one of the following arms: arm 1, zidovudine (AZT; 250 mg twice daily) plus FTC (200 mg once daily) plus efavirenz (EFV; 600 mg once daily); and arm 2, FTC (200 mg once daily) plus TDF (300 mg once daily) plus EFV (600 mg once daily).
Patients randomized to the combination of TDF plus FTC could take Truvada (TDF/FTC fixed combination tablet) once daily. Patients were allowed to switch or modify the dose of AZT and EFV for toxicity or intolerance. All patients gave informed written consent and the study was approved by the relevant institutional review boards in Thailand. Liver biopsies were optional and were collected at week 0 and week 48.
Statistical analyses
The primary end point of the study was a median log 10 copies/ml change in HBV DNA from baseline to week 48 using time-weighted area under the curve (TWAUC) analysis. Secondary end points included proportion of patients with undetectable HBV DNA at weeks 12, 24 and 48, hepatitis B e antigen (HBeAg) and HBsAg loss/ seroconversion rates, median change from baseline in HIV type-1 (HIV-1) RNA and CD4 + T-cell count (cells/ mm 3 ), median change in ALT and time to ALT normalization over 48 weeks, development of HBV resistance mutations at week 48 and rate of hepatic flares. All analyses were performed on an intention-to-treat (ITT) basis. Hepatic flares were defined as an increase in ALT or aspartate aminotransferase levels from a baseline of >5×ULN or >100 U/l from baseline if abnormal at entry. Treatment arms were compared using the Wilcoxon signed-rank test for continuous variables and Fisher's exact test for dichotomous variables. All tests were twosided and P<0.05 was considered statistically significant.
Laboratory methods
Safety bloods (haematology, biochemistry and clotting), HBV serology, T-cell subsets and HIV-1 RNA were performed at the local laboratory (HIV-NAT; Bangkok, Thailand).
HBV DNA quantification was performed at a central laboratory (Victorian Infectious Diseases Laboratory, Melbourne, Australia). HBV DNA measurement was performed on all samples using the Versant HBV DNA 3.0 bDNA assay (Bayer HealthCare, Tarrytown, NY, USA). The linear dynamic range of the assay was from 2×10 3 to 1×10 8 copies/ml (3.6×10 2 -1.8×10 7 IU/ ml). For samples below the lower limit of detection on the bDNA assay, repeat testing was performed using the COBAS ® TaqMan ® HBV Test (Roche Diagnostics, Branchburg, NJ, USA). Using a manual extraction procedure, the lower limit of quantification of this assay was approximately 170 copies/ml (30 IU/ml). Liver biopsy was not mandated by the study protocol, but was recommended for HBV disease assessment. Histological scoring was performed initially by a Thai pathologist and then subsequently by an independent pathologist in Australia who was blinded to the results. Where histological scores differed between the two pathologists by more than two fibrosis stages, the biopsies were scored again by a third independent pathologist in Australia.
Results
Demographics
A total of 19 Thai patients participated in this study. Three patients had HBV DNA<100,000 copies/ml at baseline; therefore, only 16 patients were included in this analysis. Baseline characteristics of enrolled patients are given in Table 1 . Six patients were treated with AZT/FTC/EFV (arm 1) and 10 patients were treated with TDF/FTC/EFV (arm 2). The study group was predominantly male (75%), the majority of patients identified heterosexual exposure (75%) as the most likely route of HIV-1 infection and 50% had a history of chronic HBV infection in their family. The median age of the patients was 34 years (interquartile range [IQR] 30-39) with a median body weight of 55 kg (IQR 51-62). The median baseline CD4 + T-cell count was 64 cells/µl (IQR 36-172) and the median HIV-1 RNA was 4.90 log 10 copies/ml (4.58-5.44). Of the cohort, 16% had a prior AIDS-defining illness (CDC classification C) and 63% had CDC classification B, with 58% and 53% of the group on cotrimoxazole and fluconazole treatment, respectively.
Baseline HBV DNA levels were high at a median of 8.76 log 10 copies/ml (IQR 8.45-8.82) and 11 (69%) patients were HBeAg-positive. There was no significant difference in baseline HBV DNA levels between HBeAg-positive and HBeAg-negative patients (8.0 log 10 copies/ml versus 7.1 log 10 copies/ml; P=0.09). Despite high HBV DNA levels at baseline, the median ALT was only 42 U/l (IQR 32-76) and almost one-half (44%) of patients had normal ALT levels at baseline. A total of 12 (81%) patients underwent liver biopsy at study entry and overall liver disease was mild. The median inflammatory activity (A) score was 1 (range 0-3) and the fibrosis score (F) was 1.5 (range 0-4). Only three patients had an F-score of 3/4, consistent with advanced fibrosis. Of our patients, 15 (94%) were coinfected with hepatitis B genotype C and only 1 patient had genotype B.
HBV DNA and serological response
There was a significantly greater reduction in timeweighted median change in HBV DNA over 48 weeks of study in the TDF/FTC group (-5.32 log 10 copies/ml [IQR -6.19--5.13]) compared with the FTC group (-3.25 log 10 copies/ml [IQR -5.43--2.66]; P=0.03; Figure 1 ). The proportion of patients with HBV DNA <170 copies/ml (30 IU/ml) at 48 weeks by ITT analysis was significantly higher in the TDF/FTC group than in the FTC group (90% versus 33%; P=0.036). Of the five patients who had detectable HBV DNA at 48 weeks (HBV DNA 4.21-8.05 log 10 copies/ml), none had experienced undetectable viral load or viral rebound and four were receiving FTC only. The median HBV DNA reduction in these five patients was -3.66 log 10 copies/ml (range -5.43--0.76). All patients had evidence of wild-type virus with no mutations detected in HBV polymerase. Each of these five patients had HIV-1 RNA<50 copies/ml at week 48, which was consistent with these patients being compliant with ART.
Of the study group, 11/16 (69%) were HBeAgpositive at baseline and 3/6 (50%) of HBeAg-positive patients randomized to TDF/FTC lost HBeAg (one by week 12 and two by week 24). Two of these patients developed antibody against HBeAg (anti-HBe) at the same time points. One patient randomized to FTC (1/5; 20%) lost HBeAg and developed anti-HBe at week 48. Only one patient, who was randomized to FTC, lost HBsAg at week48.
HIV-related outcomes
The median (IQR) change in CD4 + T-cell count from baseline to week 48 was 120 cells/µl (71-170) in the FTC arm and 192 cells/µl (119-271) in the TDF/FTC arm (P=0.14). The median (IQR) decrease in HIV-1 RNA to week 48 was -3.21 log 10 copies/ml (-3.76--2.86) for FTC and -3.20 log 10 copies/ml (-3.60--2.90) for TDF/FTC (P=0.87). Five (83%) of the six patients in the FTC arm and all patients in the TDF/FTC arm had HIV-1 RNA<50 copies/ml at week 48 (P=1.00). ; however, the difference was not statistically significant (P=0.70). Four patients with normal ALT levels at baseline developed abnormal ALT levels by week 48 (FTC arm n=3 and FTC/TDF arm n=1; P=0.46). A total of 13 patients underwent liver biopsy prior to taking ARV, the median (range) A and F scores were 1 (0-3) and 1.5 (0-4), respectively. Only five patients had subsequent liver biopsy at study completion (48 weeks) for comparison. Of these, the activity and fibrosis scores were unchanged in two patients (both with A0 and F0 at baseline) and an improvement in activity and fibrosis scores were seen in three patients. For F3/4 patients, only one patient had available paired biopsies at week 48, which showed improvement from fibrosis stage F3 to F1.
Biochemical and histological response
Hepatic flares and other adverse events
Hepatic flares, defined as an increase in ALT to >5×ULN or a 100 U/l increase from baseline (if abnormal at entry) was observed in 3/16 (19%) patients. For two patients receiving TDF/FTC, the flare occurred at or before week 12, and for one patient receiving FTC, the flare occurred at week 48. Both patients with hepatic flare before week 12 were HBeAg-positive at baseline, and subsequently developed anti-HBe. The patient with hepatic flare at week 48 was in the FTC arm and had an HBV DNA level of 16,267 copies/ml. There was no significant change in serum creatinine from baseline for patients in either arm. Median change in creatinine from baseline to week 48 was -0.03 mg/dl (IQR -0.14-0.05) and -0.27 mg/dl (IQR -0.67--0.12) for the FTC and TDF/FTC arms, respectively.
Discussion
In this randomized clinical trial comparing TDF/ FTC-to FTC-containing ART in HIV-HBV-coinfected patients in Thailand, we found that TDF/FTC led to significantly better control of HBV replication compared with FTC monotherapy. The median decrease in serum HBV DNA from the baseline and the number of patients reaching an undetectable HBV DNA at week 48 was significantly greater in patients receiving TDF/ FTC than FTC alone (90% and 33%, respectively).
The proportion of patients with undetectable HBV DNA in the combination TDF/FTC arm in this cohort was high (90%), higher than that seen in a previous study of TDF only (75%) or TDF/3TC-containing (64%) ARV in HIV-HBV-coinfected Thai patients [5] . Although we did not directly compare TDF/3TC to TDF/FTC in this study, enhanced potency of TDF/FTC in vivo is supported by in vitro studies, which showed greater reduction in HBV DNA following treatment with TDF/FTC compared with TDF/3TC for a hepatoma cell line chronically infected with HBV (AD38 cell line) [6] . Using isobologram analyses, TDF/FTC was associated with a synergistic effect, whereas TDF/3TC had only an additive effect [6] . Interestingly, TDF/FTC, but not TDF/3TC, has also been shown to have synergistic anti-HIV activity in vitro [7] . Enhanced potency of TDF/FTC compared with TDF/3TC was also seen in chronic woodchuck hepatitis [8] with a greater antiviral response in vivo in woodchucks receiving TDF/ FTC [8] . Whether TDF/FTC could be more efficacious than TDF/3TC in treating plasma HBV DNA needs to be determined in a further controlled trial. In this study, the proportion of patients with undetectable HBV DNA (170 copies/ml) after 48 weeks with FTC (33%) and the TWAUC for HBV DNA decrease were both significantly less than that observed with TDF/FTC. In a previously randomized study (TICO) [5] of TDF/3TC versus 3TC versus TDF in HIV-HBVcoinfected Thai patients, although there was no difference in the TWAUC for HBV DNA decrease between the three arms, a lower proportion of patients that had a HBV DNA<1,000 copies/ml at 48 weeks with 3TC monotherapy (46%) compared with TDF/3TC (75%) was observed, which would be consistent with the findings in this current study.
FTC and 3TC have a similar chemical structure and both interfere with HBV DNA polymerase activity by chain termination. One possible explanation for the different efficacies of 3TC and FTC compared with combination treatment was the use of a higher dose of 3TC (300 mg/day) than the usual recommended dose for HBV (100 mg/day) in the TICO study [5] . The anti-HBV activity efficacy of FTC is also dependent on dosage [9] , with the greatest reduction in HBV DNA (3.3 log 10 copies/ml) following treatment of HBV monoinfection with a 300 mg dose. We used the currently recommended dose of 200 mg/day for FTC, which might not be the dose with maximal anti-HBV potency.
Both FTC and 3TC have a low genetic barrier for HBV resistance and similar mutations are associated with resistance to both compounds. Consistent with these observations, we only observed inadequate virological suppression in patients receiving FTC alone. We noticed that at week 12, the HBV DNA of those four out of six patients receiving FTC alone had decreased approximately by 2.72 log 10 copies/ml (range 1.80-4.69) and after that, it plateaued. In contrast to FTC and 3TC, resistance to TDF has rarely been reported, although efficacy is reduced in individuals with prior exposure and resistance to adefovir [10] [11] [12] [13] . We did not include a TDF-only arm in this study and therefore cannot definitively conclude whether the absence of drug resistance in the TDF/FTC arm was a consequence of patients receiving TDF or combination TDF/ FTC therapy. Among all patients with detectable HBV DNA, none developed classical YMDD mutations, specifically rtM204I/V with or without the rtL180M and rtV173L [14] . Persistence of wild-type HBV DNA in patients who fail to control HBV DNA replication and/ or experience virological rebound has been previously described for 3TC [5, 15, 16] . In this setting, detection of wild-type HBV DNA usually precedes the eventual detection of a YMMD mutation. We expect that a similar mechanism might occur with FTC. All of these patients are now receiving TDF in addition to FTC and thus we are unable to determine if these patients would have eventually developed a YMMD mutation with prolonged FTC monotherapy.
As reported previously in HIV-HBV coinfection [5, 17] , we also observed high rates of HBeAg loss, 36% in HBeAg-positive patients, which was higher than previous studies in HBV-monoinfected patients treated with TDF (21%) [18] , entecavir (21%) [19] and 3TC (18%) [19] . This might be a consequence of robust immune reconstitution and acquisition of either enhanced pathogen-specific innate or adaptive immune responses following ARV. Indeed, the HIV-related virological and immunological responses to highly active antiretroviral therapy in this study were both excellent. The greater log 10 copies/ml increase in CD4 + T-cell count in the TDF/FTC group probably reflects the effects of AZT on bone marrow function and lower baseline CD4 + T-cell in the FTC group. This study is, however, limited by a small sample size, thus there was limited power to address the differences of some outcomes between the arms. Unlike our previous TICO study [5] , we did not include a TDF HBV monotherapy arm, whether TDF is comparable to TDF/ FTC in controlling HBV is therefore not known.
In conclusion, the combination of TDF/FTC had superior anti-HBV efficacy compared with FTC alone in HIV-HBV-coinfected patients. Our findings support the current recommended guidelines that combination therapy with TDF/FTC is an appropriate first-line option for HIV-HBV-coinfected patients.
